Open AccessVirological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort
Author(s) -
Linda Wittkop,
Dominique Breilh,
Daniel da Silva,
Pierre Duffau,
P. Mercié,
Isabelle Raymond,
Guerric Anies,
Hervé Fleury,
Marie-Claude Saux,
François Dabis,
Catherine Fagard,
Rodolphe Thièbaut,
Bernard Masquelier,
Isabelle Pellegrin
Publication year - 2009
Publication title -
the journal of antimicrobial chemotherapy/journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkp114
Subject(s) - raltegravir , medicine , interquartile range , regimen , cohort , viral load , gastroenterology , cohort study , human immunodeficiency virus (hiv) , immunology , antiretroviral therapy
The efficacy of raltegravir plus optimized background therapy (OBT) has been demonstrated for antiretroviral (ARV)-experienced HIV-1-infected patients in randomized clinical trials. We studied viro-immunological response, pharmacokinetic parameters and genotypic test results in an observational cohort of multiple ARV class-experienced patients starting a raltegravir-based regimen.